 |
|  |
Jan-03-19 | Upgrade |
Janney |
Neutral → Buy |
|
|
Nov-02-18 | Upgrade |
Piper Jaffray |
Neutral → Overweight |
|
|
Aug-05-16 | Reiterated |
Mizuho |
Buy |
$11 → $12 |
|
Aug-05-16 | Reiterated |
Cantor Fitzgerald |
Buy |
$13 → $11 |
|
May-05-16 | Reiterated |
Mizuho |
Buy |
$8 → $11 |
|
Apr-12-16 | Reiterated |
Leerink Partners |
Outperform |
$20 → $15 |
|
Jan-07-16 | Initiated |
Deutsche Bank |
Buy |
$18 |
|
Oct-30-15 | Upgrade |
Cantor Fitzgerald |
Hold → Buy |
$15 → $12 |
|
Oct-30-15 | Reiterated |
Mizuho |
Neutral |
$15 → $8 |
|
Aug-27-15 | Initiated |
Cantor Fitzgerald |
Hold |
|
|
Aug-07-15 | Reiterated |
Mizuho |
Neutral |
$30 → $15 |
|
Aug-07-15 | Downgrade |
Piper Jaffray |
Overweight → Neutral |
|
|
May-08-15 | Reiterated |
Maxim Group |
Buy |
$52 → $44 |
|
May-08-15 | Downgrade |
Mizuho |
Buy → Neutral |
$50 → $30 |
|
May-06-14 | Reiterated |
Maxim Group |
Buy |
$65 → $52 |
|
Apr-23-14 | Upgrade |
Mizuho |
Neutral → Buy |
$43 → $50 |
|
Mar-21-14 | Reiterated |
Maxim Group |
Buy |
$52 → $65 |
|
Feb-03-14 | Reiterated |
Oppenheimer |
Outperform |
$46 → $52 |
|
Jan-14-14 | Reiterated |
Mizuho |
Neutral |
$30 → $43 |
|
Dec-18-13 | Reiterated |
Maxim Group |
Buy |
$33 → $42 |
|
|
 |
Feb-12-19 07:00PM | Fluidigm Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire |
02:23PM | Fluidigm Corporation (NASDAQ:FLDM): Is It A Good Long Term Opportunity? Simply Wall St. |
Feb-11-19 05:03PM | The 1 Stock I'd Buy Right Now Motley Fool |
Feb-08-19 06:45PM | Edited Transcript of FLDM earnings conference call or presentation 7-Feb-19 10:00pm GMT Thomson Reuters StreetEvents +9.36% |
03:55PM | Here's Why Fluidigm Rose as Much as 14.2% Today Motley Fool |
Feb-07-19 08:09PM | Fluidigm Corp (FLDM) Q4 2018 Earnings Conference Call Transcript Motley Fool |
06:50PM | Fluidigm (FLDM) Reports Q4 Loss, Tops Revenue Estimates Zacks |
05:57PM | Fluidigm: 4Q Earnings Snapshot Associated Press |
04:05PM | Fluidigm Announces Fourth Quarter and Full Year 2018 Financial Results GlobeNewswire |
09:00AM | Fluidigm Announces Co-Marketing Agreement with Indica Labs to Offer Platform for Imaging Mass Cytometry Data Analysis to Aid Novel Digital Pathology Investigations GlobeNewswire |
08:30AM | Fluidigm Announces Participation in Life Science/Pharma and Academic Consortium to Study T Cell-Driven Immune-Mediated Inflammatory Diseases GlobeNewswire |
Jan-31-19 08:30AM | Fluidigm Introduces REAP-Seq for Multi-Omic Single-Cell Analysis on the C1 GlobeNewswire |
Jan-24-19 07:55AM | Consolidated Research: 2019 Summary Expectations for Marriott International, Calavo Growers, Kinsale Capital Group, Fluidigm, Goldman Sachs BDC, and Stemline Therapeutics Fundamental Analysis, Key Performance Indications GlobeNewswire |
Jan-14-19 04:05PM | Fluidigm Announces Conference Call and Webcast of Fourth Quarter and Full Year 2018 Financial Results GlobeNewswire |
Jan-08-19 08:30AM | Caprion Biosciences Offers Mass Cytometry CRO Services to Advance Biomarker Discovery and Immune Monitoring GlobeNewswire +5.03% |
Dec-23-18 09:49PM | Do Hedge Funds Love Fluidigm Corporation (FLDM)? Insider Monkey |
Dec-14-18 04:05PM | Fluidigm Announces Closing of Public Offering of 9,372,500 Shares of Common Stock Including Full Exercise of Option to Purchase Additional Shares GlobeNewswire |
Dec-12-18 01:01AM | Fluidigm Announces Pricing of Public Offering of 8,150,000 Shares of Common Stock GlobeNewswire |
Dec-11-18 04:01PM | Fluidigm Announces Commencement of Public Offering of Common Stock GlobeNewswire |
Dec-10-18 04:23PM | Edited Transcript of FLDM earnings conference call or presentation 1-Nov-18 9:00pm GMT Thomson Reuters StreetEvents |
Dec-05-18 09:15AM | Recent Gains Cut in Half on Trade, Yield Curve Fears Zacks |
Nov-12-18 04:05PM | Fluidigm to Participate in the 30th Annual Piper Jaffray Healthcare Conference GlobeNewswire -5.24% |
Nov-09-18 04:05PM | Fluidigm Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire |
Nov-08-18 08:30AM | Fluidigm Showcases Immuno-Oncology Innovations for Translational and Clinical Research at SITC 2018 GlobeNewswire |
Nov-07-18 04:11PM | Fluidigm Recognized as a Company to Watch in 2019 GlobeNewswire +6.15% |
Nov-06-18 08:35AM | Research Report Identifies Exelon, La Jolla Pharmaceutical, Kennedy-Wilson, Fluidigm, Telefonica SA, and Cognex with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire |
Nov-01-18 07:50PM | Fluidigm (FLDM) Reports Q3 Loss, Tops Revenue Estimates Zacks |
06:43PM | Fluidigm: 3Q Earnings Snapshot Associated Press |
04:05PM | Fluidigm Announces Third Quarter 2018 Financial Results GlobeNewswire |
08:30AM | Sirona Dx Introduces Imaging Mass Cytometry Services to Advance Biomarker Discovery and Therapeutic Development GlobeNewswire |
Oct-31-18 08:30AM | Laura Clague Named to Fluidigm Board of Directors GlobeNewswire |
Oct-25-18 08:30AM | Foundational 10,000 Immunomes Project Uses Mass Cytometry to Establish a Reference Standard for the Human Immune System GlobeNewswire |
Oct-16-18 07:45AM | Market Trends Toward New Normal in Globant S.A, EZCORP, Earthstone Energy, SPX, Fluidigm, and MAG Silver Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire |
Oct-04-18 08:30AM | Fluidigm Announces Agreement with DNA Software to Offer Secondary CNV Analysis for Biomark HD GlobeNewswire |
Oct-01-18 04:15PM | Fluidigm Announces Conference Call and Webcast of Third Quarter 2018 Financial Results GlobeNewswire |
Sep-27-18 04:05PM | Fluidigm Introduces Single-Cell Total RNA Sequencing Applications for C1 GlobeNewswire |
Sep-10-18 08:30AM | Fluidigm Announces Co-Marketing Agreement with Visiopharm to Expand and Simplify Imaging Mass Cytometry Data Analysis GlobeNewswire |
Sep-07-18 07:30AM | Fluidigm Partners with GenomOncology to Provide a Comprehensive Immuno-Oncology Gene Expression Solution on Biomark HD GlobeNewswire |
Sep-05-18 06:00PM | Fluidigm to Participate at Upcoming Investor Events in September GlobeNewswire |
Aug-15-18 07:45AM | Detailed Research: Economic Perspectives on Middlesex Water, Farmer Brothers, Fluidigm, QCR, Revlon, and Gladstone Land What Drives Growth in Today's Competitive Landscape GlobeNewswire |
Aug-09-18 08:30AM | Fluidigm to Host 2nd Annual Imaging Mass Cytometry User Group Meeting GlobeNewswire |
Aug-06-18 04:05PM | Fluidigm Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire |
Aug-03-18 05:25PM | Edited Transcript of FLDM earnings conference call or presentation 2-Aug-18 9:00pm GMT Thomson Reuters StreetEvents |
09:25AM | Fluidigm (FLDM) Reports Q2 Loss, Tops Revenue Estimates Zacks |
05:05AM | Fluidigm: 2Q Earnings Snapshot Associated Press |
Aug-02-18 04:05PM | Fluidigm Announces Second Quarter 2018 Financial Results GlobeNewswire |
Jul-31-18 08:30AM | Fluidigm Introduces a Lower-Cost Workflow for Full-Length Single-Cell mRNA Sequencing on C1 GlobeNewswire +5.96% |
Jul-10-18 08:30AM | Fluidigm Announces First Multimodal Single-Cell Application for the C1 GlobeNewswire |
Jul-05-18 04:05PM | Fluidigm Announces Conference Call and Webcast of Second Quarter 2018 Financial Results GlobeNewswire |
Jun-29-18 10:59AM | Zacks.com featured highlights include: Hershey, Polaris, Lithia, Fluidigm and Univar Zacks |
Jun-28-18 07:32AM | Bet on Rising P/E Investing With These 5 Top-Ranked Stocks Zacks |
Jun-26-18 08:30AM | David King Joins Fluidigm as Vice President, Research and Development, Genomics GlobeNewswire |
Jun-13-18 02:12PM | Edited Transcript of FLDM earnings conference call or presentation 3-May-18 9:00pm GMT Thomson Reuters StreetEvents |
Jun-07-18 11:14AM | Fluidigm Corporations (NASDAQ:FLDM) Insiders Ramped Up Holdings Should You? Simply Wall St. |
07:00AM | Fluidigm and Genomenon to Offer Evidence-Based Genomic Panel Design Service GlobeNewswire |
Jun-05-18 06:30AM | Fluidigm Releases Sample Identification Genotyping Panel for Translational and Clinical Research GlobeNewswire |
May-11-18 07:10AM | Free Research Report as Thermo Fisher Scientifics Quarterly Revenue Surged 23%; Adjusted EPS Jumped 20% ACCESSWIRE |
May-10-18 07:02PM | Fluidigm Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire |
May-09-18 04:05PM | Fluidigm to Participate in Upcoming Investor Events GlobeNewswire |
May-03-18 06:14PM | Fluidigm: 1Q Earnings Snapshot Associated Press +5.61% |
04:04PM | Fluidigm Announces First Quarter Financial Results and Operational Progress GlobeNewswire |
Apr-30-18 07:45AM | Report: Developing Opportunities within Fluidigm, MaxLinear, Southern National Bancorp of Virginia, Power Integrations, Hersha Hospitality Trust, and W.R. Berkley Future Expectations, Projections Moving into 2018 GlobeNewswire |
Apr-23-18 08:00AM | Brad Kreger Joins Fluidigm as Senior Vice President, Global Operations GlobeNewswire |
Apr-19-18 08:42PM | Has Fluidigm Corporation (NASDAQ:FLDM) Improved Earnings Growth In Recent Times? Simply Wall St. |
04:05PM | Fluidigm to Report Q1 2018 Financial Results and Host Conference Call GlobeNewswire |
Apr-13-18 04:10PM | Fluidigm Introduces High-Parameter Maxpar Immune Monitoring Panel for Translational and Clinical Research GlobeNewswire |
Apr-12-18 09:29AM | Fluidigm Releases CFTR Next-Generation Sequencing Library Prep Assay for Use With the Juno System GlobeNewswire |
Mar-19-18 07:50AM | Report: Exploring Fundamental Drivers Behind Fluidigm, Acuity Brands, TTEC, Actuant, Equity Lifestyle Properties, and Stemline Therapeutics New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire |
Mar-13-18 08:54AM | What Investors Should Know About Fluidigm Corporations (NASDAQ:FLDM) Financial Strength Simply Wall St. |
07:45AM | Fluidigm Announces Exchange of Convertible Notes GlobeNewswire |
Mar-02-18 07:45AM | Fluidigm Announces Exchange of Convertible Notes GlobeNewswire -8.47% |
Feb-27-18 05:03PM | What Should Investors Know About The Future Of Fluidigm Corporations (NASDAQ:FLDM) Business? Simply Wall St. |
Feb-22-18 06:36PM | Edited Transcript of FLDM earnings conference call or presentation 8-Feb-18 10:00pm GMT Thomson Reuters StreetEvents -6.08% |
Feb-15-18 07:30AM | Wired News Charles River Labs Inked an Agreement to Acquire MPI Research ACCESSWIRE +10.85% |
Feb-14-18 04:05PM | Fluidigm to Participate in Upcoming Health Care Investor Conferences GlobeNewswire |
07:20AM | Free Post Earnings Research Report: Thermo Fishers Quarterly Revenue Surged 22%; Adjusted EPS Advanced 16% ACCESSWIRE |
Feb-08-18 09:07PM | Fluidigm reports 4Q loss Associated Press |
04:05PM | Fluidigm Announces Fourth Quarter and Full Year 2017 Financial Results and Operational Progress GlobeNewswire |
12:50PM | Fluidigm Corporation to Host Earnings Call ACCESSWIRE |
10:32AM | Is Fluidigm Corporation (NASDAQ:FLDM) Undervalued? Simply Wall St. |
Jan-25-18 04:05PM | Fluidigm to Report Q4 and Full Year 2017 Financial Results GlobeNewswire |
Jan-09-18 07:30AM | Detailed Research: Economic Perspectives on Fluidigm, Stemline Therapeutics, NeoGenomics, CVR Energy, W.R. Berkley, and Mack-Cali Realty What Drives Growth in Today's Competitive Landscape GlobeNewswire |
Jan-01-18 11:35AM | ETFs with exposure to Fluidigm Corp. : January 1, 2018 Capital Cube |
Dec-29-17 05:55PM | Was Fluidigm Corporations (NASDAQ:FLDM) Earnings Growth Better Than Industry? Simply Wall St. |
Dec-21-17 04:05PM | Fluidigm Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire |
Dec-19-17 01:01PM | ETFs with exposure to Fluidigm Corp. : December 19, 2017 Capital Cube |
Dec-07-17 01:44PM | ETFs with exposure to Fluidigm Corp. : December 7, 2017 Capital Cube |
Nov-27-17 01:37PM | ETFs with exposure to Fluidigm Corp. : November 27, 2017 Capital Cube +6.08% |
Nov-24-17 11:34PM | Edited Transcript of FLDM earnings conference call or presentation 2-Nov-17 9:00pm GMT Thomson Reuters StreetEvents |
Nov-21-17 09:06AM | Fluidigm Corp. :FLDM-US: Earnings Analysis: Q3, 2017 By the Numbers : November 21, 2017 Capital Cube |
Nov-14-17 04:05PM | Fluidigm to Participate in the 29th Annual Piper Jaffray Healthcare Conference GlobeNewswire +5.38% |
Nov-02-17 06:19PM | Fluidigm reports 3Q loss Associated Press |
04:05PM | Fluidigm Announces Third Quarter Financial Results and Operational Progress GlobeNewswire |
12:30PM | Fluidigm Corporation to Host Earnings Call ACCESSWIRE |
Oct-31-17 08:25PM | Does Fluidigm Corporations (FLDM) Debt Level Pose A Serious Problem? Simply Wall St. |
Oct-25-17 09:58AM | ETFs with exposure to Fluidigm Corp. : October 25, 2017 Capital Cube |
Oct-24-17 08:10AM | Fluidigm Announces Agreement With the University of Zurich to Distribute histoCAT for Multiparameter Imaging Mass Cytometry Data Analysis GlobeNewswire |
08:00AM | Fluidigm Introduces Imaging Mass Cytometry System for Highly Multiplexed Protein Detection in Tissues GlobeNewswire |
Oct-19-17 04:05PM | Fluidigm to Report Q3 2017 Financial Results and Host Conference Call GlobeNewswire |
Oct-18-17 09:00AM | Fluidigm to Unveil High-Parameter Tissue Imaging System GlobeNewswire |
|
|
|
 |
Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research in the United States and Europe. It offers analytical systems comprising Helios system, Hyperion imaging system, and Hyperion tissue imager; and assays and reagents, including Maxpar reagents. The company also provides preparatory instruments, such as access array and Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell genomics that comprise C1 system, Polaris system, C1 IFCs, and Polaris IFC. It sells instruments and consumables, including IFCs, assays, and reagents to academic institutions, clinical research laboratories, and contract research organizations, as well as biopharmaceutical, biotechnology, and agricultural biotechnology companies. The company was formerly known as Mycometrix Corporation and changed its name to Fluidigm Corporation in April 2001. Fluidigm Corporation was founded in 1999 and is headquartered in South San Francisco, California. |
 |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
LEVIN CAPITAL STRATEGIES, L.P. | Passive Investor | Dec 24 | Buy | 7.79 | 85 | 662 | 10,473,809 | Dec 26 03:40 PM | LEVIN CAPITAL STRATEGIES, L.P. | Passive Investor | Dec 20 | Buy | 7.42 | 576 | 4,273 | 10,413,365 | Dec 26 03:40 PM | LEVIN CAPITAL STRATEGIES, L.P. | Passive Investor | Dec 19 | Buy | 7.86 | 128 | 1,006 | 10,412,789 | Dec 20 05:07 PM | LEVIN CAPITAL STRATEGIES, L.P. | Passive Investor | Dec 18 | Buy | 7.71 | 36 | 278 | 10,412,661 | Dec 20 05:07 PM | LEVIN CAPITAL STRATEGIES, L.P. | Passive Investor | Dec 14 | Buy | 7.81 | 41 | 320 | 10,412,625 | Dec 18 03:09 PM | LEVIN CAPITAL STRATEGIES, L.P. | Passive Investor | Dec 12 | Buy | 6.75 | 1,000,000 | 6,750,000 | 10,404,641 | Dec 14 06:14 PM | LEVIN CAPITAL STRATEGIES, L.P. | Passive Investor | Dec 10 | Buy | 7.72 | 35,000 | 270,200 | 9,970,342 | Dec 11 03:26 PM | LEVIN CAPITAL STRATEGIES, L.P. | Passive Investor | Dec 07 | Buy | 7.95 | 33 | 262 | 9,935,342 | Dec 11 03:26 PM | Linthwaite Stephen Christopher | President & CEO | Nov 20 | Option Exercise | 0.00 | 12,562 | 0 | 146,650 | Nov 21 09:07 PM | Khadder Nicholas | See Remarks | Nov 20 | Option Exercise | 0.00 | 4,901 | 0 | 32,530 | Nov 21 09:06 PM | McPhail Steven | Chief Commercial Officer | Nov 20 | Option Exercise | 0.00 | 3,720 | 0 | 52,055 | Nov 21 09:06 PM | JOG VIKRAM | CHIEF FINANCIAL OFFICER | Nov 20 | Option Exercise | 0.00 | 5,051 | 0 | 34,217 | Nov 21 09:07 PM | LEVIN CAPITAL STRATEGIES, L.P. | Passive Investor | Nov 14 | Buy | 7.55 | 47,768 | 360,696 | 9,809,695 | Nov 16 03:01 PM | LEVIN CAPITAL STRATEGIES, L.P. | Passive Investor | Nov 08 | Buy | 7.84 | 127 | 996 | 9,761,927 | Nov 13 03:42 PM | LEVIN CAPITAL STRATEGIES, L.P. | Passive Investor | Nov 06 | Buy | 7.40 | 855 | 6,326 | 9,761,800 | Nov 08 03:00 PM | LEVIN CAPITAL STRATEGIES, L.P. | Passive Investor | Oct 26 | Buy | 7.19 | 2,599 | 18,680 | 11,337,342 | Oct 26 12:30 PM | LEVIN CAPITAL STRATEGIES, L.P. | Passive Investor | Oct 25 | Buy | 7.21 | 7,363 | 53,095 | 11,334,743 | Oct 26 12:30 PM | LEVIN CAPITAL STRATEGIES, L.P. | Passive Investor | Oct 19 | Buy | 7.51 | 25,209 | 189,231 | 11,327,380 | Oct 23 04:19 PM | LEVIN CAPITAL STRATEGIES, L.P. | Passive Investor | Oct 12 | Buy | 7.45 | 18 | 134 | 11,302,171 | Oct 15 06:05 PM | LEVIN CAPITAL STRATEGIES, L.P. | Passive Investor | Oct 11 | Buy | 7.44 | 53 | 394 | 11,302,153 | Oct 15 06:05 PM | LEVIN CAPITAL STRATEGIES, L.P. | Passive Investor | Oct 09 | Buy | 7.29 | 34,896 | 254,217 | 11,302,100 | Oct 11 04:31 PM | LEVIN CAPITAL STRATEGIES, L.P. | Passive Investor | Oct 01 | Buy | 7.56 | 24 | 181 | 11,267,204 | Oct 03 06:16 PM | LEVIN CAPITAL STRATEGIES, L.P. | Passive Investor | Sep 27 | Buy | 7.53 | 52 | 392 | 11,296,850 | Oct 01 03:19 PM | LEVIN CAPITAL STRATEGIES, L.P. | Passive Investor | Sep 25 | Buy | 7.98 | 2,940 | 23,447 | 11,296,798 | Sep 27 05:08 PM | LEVIN CAPITAL STRATEGIES, L.P. | Passive Investor | Sep 19 | Buy | 8.22 | 40 | 329 | 11,293,858 | Sep 21 03:00 PM | LEVIN CAPITAL STRATEGIES, L.P. | Passive Investor | Sep 11 | Buy | 8.42 | 17 | 143 | 11,465,884 | Sep 13 04:00 PM | LEVIN CAPITAL STRATEGIES, L.P. | Passive Investor | Sep 06 | Buy | 7.84 | 49 | 384 | 11,465,867 | Sep 07 03:21 PM | LEVIN CAPITAL STRATEGIES, L.P. | Passive Investor | Sep 05 | Buy | 7.85 | 152 | 1,193 | 11,465,818 | Sep 07 03:21 PM | LEVIN CAPITAL STRATEGIES, L.P. | Passive Investor | Aug 30 | Buy | 7.86 | 18 | 141 | 11,465,666 | Sep 04 06:47 PM | Linthwaite Stephen Christopher | President & CEO | Aug 20 | Option Exercise | 0.00 | 12,562 | 0 | 138,433 | Aug 22 05:00 PM | Khadder Nicholas | See Remarks | Aug 20 | Option Exercise | 0.00 | 4,901 | 0 | 16,022 | Aug 22 04:59 PM | McPhail Steven | Chief Commercial Officer | Aug 20 | Option Exercise | 0.00 | 3,722 | 0 | 38,002 | Aug 22 05:00 PM | JOG VIKRAM | CHIEF FINANCIAL OFFICER | Aug 20 | Option Exercise | 0.00 | 5,051 | 0 | 20,117 | Aug 22 05:01 PM | LEVIN CAPITAL STRATEGIES, L.P. | Passive Investor | Aug 15 | Buy | 6.78 | 25,500 | 172,880 | 11,465,648 | Aug 17 01:23 PM | LEVIN CAPITAL STRATEGIES, L.P. | Passive Investor | Aug 08 | Buy | 6.76 | 21 | 142 | 11,720,361 | Aug 10 02:46 PM | LEVIN CAPITAL STRATEGIES, L.P. | Passive Investor | Aug 02 | Buy | 6.36 | 29 | 184 | 11,720,340 | Aug 06 03:41 PM | LEVIN CAPITAL STRATEGIES, L.P. | Passive Investor | Jul 31 | Buy | 6.40 | 2,692 | 17,230 | 11,720,311 | Aug 02 04:05 PM | LEVIN CAPITAL STRATEGIES, L.P. | Passive Investor | Jul 27 | Buy | 6.14 | 20,029 | 123,071 | 11,717,619 | Jul 31 03:19 PM | LEVIN CAPITAL STRATEGIES, L.P. | Passive Investor | Jul 12 | Buy | 6.27 | 54 | 339 | 11,697,536 | Jul 16 02:07 PM | LEVIN CAPITAL STRATEGIES, L.P. | Passive Investor | Jul 03 | Buy | 6.00 | 61 | 366 | 11,697,536 | Jul 06 03:35 PM | LEVIN CAPITAL STRATEGIES, L.P. | Passive Investor | Jun 22 | Buy | 5.45 | 34 | 185 | 11,697,475 | Jul 06 03:35 PM | LEVIN CAPITAL STRATEGIES, L.P. | Passive Investor | Jun 19 | Buy | 4.72 | 10,593 | 49,960 | 11,697,441 | Jun 21 07:31 PM | LEVIN CAPITAL STRATEGIES, L.P. | Passive Investor | Jun 18 | Buy | 4.76 | 89,544 | 426,086 | 11,687,194 | Jun 19 08:50 PM | LEVIN CAPITAL STRATEGIES, L.P. | Passive Investor | Jun 15 | Buy | 4.93 | 32,005 | 157,898 | 11,600,578 | Jun 19 08:50 PM | LEVIN CAPITAL STRATEGIES, L.P. | Passive Investor | Jun 13 | Buy | 4.95 | 149,215 | 738,742 | 11,569,391 | Jun 14 06:28 PM | LEVIN CAPITAL STRATEGIES, L.P. | Passive Investor | Jun 12 | Buy | 5.00 | 500 | 2,500 | 11,422,857 | Jun 14 06:28 PM | LEVIN CAPITAL STRATEGIES, L.P. | Passive Investor | Jun 08 | Buy | 5.51 | 40,763 | 224,597 | 11,422,357 | Jun 11 05:41 PM | LEVIN CAPITAL STRATEGIES, L.P. | Passive Investor | Jun 07 | Buy | 5.54 | 15,000 | 83,030 | 11,381,594 | Jun 11 05:41 PM | Burbach Gerhard F | Director | May 30 | Option Exercise | 0.00 | 8,000 | 0 | 32,115 | Jun 01 08:55 PM | JONES PATRICK S | Director | May 30 | Option Exercise | 0.00 | 8,000 | 0 | 13,000 | Jun 01 08:57 PM | COLELLA SAMUEL D | Director | May 30 | Option Exercise | 0.00 | 8,000 | 0 | 79,923 | Jun 01 08:55 PM | Paya Carlos V | Director | May 30 | Option Exercise | 0.00 | 8,000 | 0 | 23,734 | Jun 01 08:54 PM | BARTHELEMY NICOLAS | Director | May 30 | Option Exercise | 0.00 | 8,000 | 0 | 34,362 | Jun 01 08:56 PM | LEVIN CAPITAL STRATEGIES, L.P. | Passive Investor | May 29 | Buy | 5.60 | 1,200 | 6,714 | 11,247,392 | May 31 05:36 PM | LEVIN CAPITAL STRATEGIES, L.P. | Passive Investor | May 25 | Buy | 5.66 | 2,870 | 16,244 | 11,251,041 | May 29 03:18 PM | LEVIN CAPITAL STRATEGIES, L.P. | Passive Investor | May 24 | Buy | 5.70 | 7,100 | 40,449 | 11,248,171 | May 29 03:18 PM | McPhail Steven | Chief Commercial Officer | May 20 | Option Exercise | 0.00 | 2,396 | 0 | 34,999 | May 22 09:02 PM | Khadder Nicholas | See Remarks | May 20 | Option Exercise | 0.00 | 2,650 | 0 | 10,978 | May 22 09:01 PM | JOG VIKRAM | CHIEF FINANCIAL OFFICER | May 20 | Option Exercise | 0.00 | 2,800 | 0 | 16,035 | May 22 09:02 PM | Linthwaite Stephen Christopher | President & CEO | May 20 | Option Exercise | 0.00 | 4,750 | 0 | 122,514 | May 22 09:02 PM | LEVIN CAPITAL STRATEGIES, L.P. | Passive Investor | May 09 | Buy | 5.37 | 16,900 | 90,836 | 11,241,071 | May 11 05:01 PM | LEVIN CAPITAL STRATEGIES, L.P. | Passive Investor | May 08 | Buy | 5.47 | 33,000 | 180,431 | 11,226,078 | May 09 03:56 PM | LEVIN CAPITAL STRATEGIES, L.P. | Passive Investor | May 07 | Buy | 5.60 | 44,700 | 250,164 | 11,196,801 | May 09 03:56 PM | LEVIN CAPITAL STRATEGIES, L.P. | Passive Investor | May 04 | Buy | 5.68 | 89,800 | 510,482 | 11,158,071 | May 07 05:20 PM | LEVIN CAPITAL STRATEGIES, L.P. | Passive Investor | May 03 | Buy | 5.85 | 2,405 | 14,069 | 11,081,432 | May 07 05:20 PM | LEVIN CAPITAL STRATEGIES, L.P. | Passive Investor | Apr 30 | Buy | 5.92 | 6,649 | 39,370 | 11,079,027 | May 02 07:04 PM | LEVIN CAPITAL STRATEGIES, L.P. | Passive Investor | Apr 26 | Buy | 5.96 | 9,609 | 57,271 | 11,072,378 | Apr 30 05:15 PM | LEVIN CAPITAL STRATEGIES, L.P. | Passive Investor | Apr 25 | Buy | 5.92 | 2,400 | 14,206 | 11,062,769 | Apr 26 04:24 PM | LEVIN CAPITAL STRATEGIES, L.P. | Passive Investor | Apr 24 | Buy | 5.95 | 1,300 | 7,733 | 11,060,369 | Apr 26 04:24 PM | LEVIN CAPITAL STRATEGIES, L.P. | Passive Investor | Apr 20 | Buy | 5.89 | 500 | 2,947 | 11,059,069 | Apr 24 06:17 PM | LEVIN CAPITAL STRATEGIES, L.P. | Passive Investor | Apr 19 | Buy | 5.92 | 10,013 | 59,325 | 11,058,569 | Apr 24 06:17 PM | LEVIN CAPITAL STRATEGIES, L.P. | Passive Investor | Apr 02 | Buy | 5.73 | 7,240 | 41,496 | 11,048,556 | Apr 04 03:57 PM | LEVIN CAPITAL STRATEGIES, L.P. | Passive Investor | Mar 26 | Buy | 5.74 | 13,300 | 76,369 | 11,044,231 | Mar 27 05:20 PM | BARTHELEMY NICOLAS | Director | Mar 23 | Option Exercise | 0.00 | 2,500 | 0 | 26,362 | Mar 26 08:57 PM | Paya Carlos V | Director | Mar 23 | Option Exercise | 0.00 | 2,500 | 0 | 15,734 | Mar 26 08:57 PM | LEVIN CAPITAL STRATEGIES, L.P. | Passive Investor | Mar 23 | Buy | 5.97 | 7,720 | 46,096 | 11,030,931 | Mar 27 05:20 PM | LEVIN CAPITAL STRATEGIES, L.P. | Passive Investor | Mar 09 | Buy | 6.63 | 107 | 709 | 11,023,211 | Mar 12 06:37 PM | LEVIN CAPITAL STRATEGIES, L.P. | Passive Investor | Mar 08 | Buy | 6.48 | 40,000 | 259,116 | 11,023,104 | Mar 12 06:37 PM | LEVIN CAPITAL STRATEGIES, L.P. | Passive Investor | Mar 05 | Buy | 6.17 | 7,500 | 46,273 | 10,983,104 | Mar 06 08:24 PM | LEVIN CAPITAL STRATEGIES, L.P. | Passive Investor | Mar 02 | Buy | 6.24 | 248,655 | 1,552,475 | 10,975,756 | Mar 05 06:20 PM | LEVIN CAPITAL STRATEGIES, L.P. | Passive Investor | Mar 01 | Buy | 6.72 | 1,700 | 11,426 | 10,733,428 | Mar 05 06:20 PM | LEVIN CAPITAL STRATEGIES, L.P. | Passive Investor | Feb 28 | Buy | 6.80 | 8,950 | 60,833 | 10,731,728 | Mar 01 05:38 PM | LEVIN CAPITAL STRATEGIES, L.P. | Passive Investor | Feb 27 | Buy | 6.87 | 5,000 | 34,337 | 10,722,778 | Mar 01 05:38 PM | LEE JENNIFER LING | See Remarks | Feb 20 | Option Exercise | 0.00 | 1,755 | 0 | 7,432 | Feb 22 04:33 PM | Linthwaite Stephen Christopher | President & CEO | Feb 20 | Option Exercise | 0.00 | 4,750 | 0 | 119,702 | Feb 22 04:32 PM | McPhail Steven | Chief Commercial Officer | Feb 20 | Option Exercise | 0.00 | 2,397 | 0 | 33,450 | Feb 22 04:32 PM | Khadder Nicholas | See Remarks | Feb 20 | Option Exercise | 0.00 | 2,650 | 0 | 9,410 | Feb 22 04:33 PM | Yow Mai Chan | See Remarks | Feb 20 | Option Exercise | 0.00 | 2,279 | 0 | 19,705 | Feb 22 04:32 PM | JOG VIKRAM | CHIEF FINANCIAL OFFICER | Feb 20 | Option Exercise | 0.00 | 3,034 | 0 | 14,474 | Feb 22 04:32 PM |
|
 |
|
 |
|